We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.43B
AUM Growth
+$209M
Cap. Flow
+$182M
Cap. Flow %
12.72%
Top 10 Hldgs %
28.58%
Holding
96
New
13
Increased
36
Reduced
31
Closed
4

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$34M
2
COR icon
Cencora
COR
+$18.2M
3
TDOC icon
Teladoc Health
TDOC
+$17.4M
4
ISRG icon
Intuitive Surgical
ISRG
+$16.6M
5
MCK icon
McKesson
MCK
+$16.1M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27M
2
ABBV icon
AbbVie
ABBV
+$14.1M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.74M
5
GKOS icon
Glaukos
GKOS
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Industrials 0.98%
3 Technology 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
26
Intuitive Surgical
ISRG
$139B
$21.4M 1.49%
87,000
+66,000
+314% +$16.6M
MRK icon
27
Merck
MRK
$323B
$20.8M 1.45%
282,960
-77,573
-22% -$5.72M
ZBH icon
28
Zimmer Biomet
ZBH
$18.7B
$20.8M 1.45%
133,900
+66,950
+100% +$10.4M
BDX icon
29
Becton Dickinson
BDX
$48.9B
$20.7M 1.44%
87,125
+41,000
+89% +$10M
TMO icon
30
Thermo Fisher Scientific
TMO
$222B
$20.5M 1.43%
45,000
+17,550
+64% +$8.38M
BMY icon
31
Bristol-Myers Squibb
BMY
$132B
$20.5M 1.43%
325,000
-15,000
-4% -$933K
COR icon
32
Cencora
COR
$62B
$19.8M 1.38%
+167,957
New +$18.2M
COO icon
33
Cooper Companies
COO
$14.9B
$19.2M 1.34%
200,000
-20,000
-9% -$1.9M
ALNY icon
34
Alnylam Pharmaceuticals
ALNY
$29B
$19.1M 1.33%
135,000
+23,300
+21% +$3.51M
MGNX icon
35
MacroGenics
MGNX
$259M
$17.4M 1.21%
545,160
-79,840
-13% -$1.94M
MCK icon
36
McKesson
MCK
$103B
$17.2M 1.2%
+88,000
New +$16.1M
ESPR
37
DELISTED
Esperion Therapeutics
ESPR
$16.6M 1.16%
592,225
– –
BAX icon
38
Baxter International
BAX
$14.4B
$16M 1.12%
190,000
-15,000
-7% -$1.19M
ITCI
39
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15.5M 1.08%
457,778
-42,222
-8% -$1.46M
NBIX icon
40
Neurocrine Biosciences
NBIX
$16.8B
$15.1M 1.05%
155,000
+5,000
+3% +$524K
HCA icon
41
HCA Healthcare
HCA
$89.6B
$14.1M 0.98%
75,000
– –
BHVN
42
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$13.7M 0.96%
200,419
-34,581
-15% -$2.8M
BMRN icon
43
BioMarin Pharmaceuticals
BMRN
$13.3B
$13.6M 0.95%
180,000
-330,000
-65% -$27M
AERI
44
DELISTED
Aerie Pharmaceuticals
AERI
$13.4M 0.93%
750,000
-100,000
-12% -$1.73M
APLS
45
DELISTED
Apellis Pharmaceuticals
APLS
$11.6M 0.81%
270,000
– –
LIVN icon
46
LivaNova
LIVN
$4.21B
$11.4M 0.8%
155,000
-35,000
-18% -$2.5M
SGEN
47
DELISTED
Seagen Inc. Common Stock
SGEN
$11.1M 0.77%
80,000
+15,000
+23% +$2.42M
XNCR icon
48
Xencor
XNCR
$1.6B
$10.1M 0.71%
235,000
-24,341
-9% -$1.15M
SGMO
49
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.59M 0.67%
765,000
-56,888
-7% -$767K
REGN icon
50
Regeneron Pharmaceuticals
REGN
$83.2B
$9.46M 0.66%
20,000
-20,000
-50% -$9.74M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rhenman & Partners Asset Management held 96 positions worth $1.43B, up 17% from $1.23B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $182M of net new capital in Q1 2021, opening 13 new positions and adding to 36 existing holdings. Its largest new stake was Cencora: 167,957 shares worth $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $27M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2021 buy was Cencora: 167,957 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Johnson & Johnson in Q1 2021, an estimated $34M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2021 reduction was BioMarin Pharmaceuticals, cutting an estimated $27M.
  • Rhenman & Partners Asset Management fully exited Agios Pharmaceuticals in Q1 2021, selling an estimated $5.63M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.43B portfolio in Q1 2021.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 4 in Q1 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 17% quarter-over-quarter to $1.43B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2021, filed 14 May 2021.